



Natural. Safe.
Proven.

Solving Presbyopia: An Increasing Global Vision Problem

Addressing a \$8 billion market opportunity.

Executive Summary



Presbyopia - The World's Most Common Vision Problem Finally Has a Natural Fix

 Identified Substantial Unmet Need

Presbyopia is the age-related loss of near vision

Over 2 billion people over 40 lose near vision

Current options are invasive and irreversible —less appealing

\$8bn market opportunity

 Validated Clinical Solution

Allotex TRANSFORM™ made of natural sterile human collagen (Allograft)

95% of patients have improved near vision

All safety endpoints achieved

EU: 4 -Year Multi -Center Clinical Data

 Validated Commercial Model

Sales in EU, Canada, Australia, South Africa, and the Middle East

Proof of reorders

Supply chain and logistics in place

2026 Plan: \$2M revenue >2000 sold implants

 Defined Regulatory Pathways

Cleared in EU, Canada and other regions

FDA IDE Approved in US

China MNPA Strategy defined

EU cleared, US & China in progress

 Scaling and Geographic Expansion

\$25M Financing Round

Highly experienced team with multiple exits in the space




Growing Revenues and market access


Transform Corneal Inlay - Adding Back What Age Took Away.

Sterile human collagen, shaped with micrometer precision, and placed safely within the cornea to restore near vision by adding tissue (allograft) - safe, natural, and proven.


Sterile Allograft implant
Diameter: 2.5 mm
Thickness: 20 micrometers



10 min in -office procedure
No additional capital equipment





Restoring vision for all distances



Clear Vision at all distances with long-term stability and safety.

98% of the patients achieved functional near vision (>20/40) without reading glasses or contact lenses



 Restores Near Vision

 Enhanced Intermediate Vision

 Maintain Distance Vision

101 Patients, Prospective, single arm non-randomised clinical trial, at 5 participating countries, monitored by an independent CRO

The Allotex team expertly guides products from launch to global markets.



Role-based leadership - Centralized governance - Built-in continuity

Architects of modern refractive surgery



Michael Mrochen,
CEO, co-founder

30+ years in refractive surgery

Dirk Mühlhoff,
Board Member

25+ years in refractive surgery

Dr. Vance Thompson
MD USA, clinical advisor

35+ years in refractive surgery

Turning precision science into a scalable business.



Evan Sherr
COO

30+ years of operations and R&D.



Francesco Mundini
Commercial Director

10+ years in vision correction



Andrew Amiel
BD/Investor Relations

20+ years in Finance, Venture Capital



Thilelli Chalal,
Sales Manager

10+ years in Eye Surgery



Maureen O'Connell
US Regulatory Consultant

30+ years in Eye Surgery



Andrea Borra
Financial Director

15+ years working experience

Turning innovation into clinical reality



Dr. Arthur Cummings
MD Ireland



Prof. Aylin Kilic
MD Turkey



Dr. Francesco Carones
MD Italy

- Michael: Successful transactions with Alcon, WaveLight, Avedro (Glaukos), and Zeiss.
- Dirk: 25 years at Zeiss, leading global refractive surgery R&D.
- Evan: Senior roles at Summit, Avedro, and other medtech/pharma firms.
- Maureen: Over 30 years of successful regulatory approvals in refractive surgery (Summit, WaveLight, Avedro, RxSight).